Milestone on the Path towards Clinical Approval
for a Potential New Therapy for Resistant Hypertension

With the launch of the baroloop Multi-Center Trial (MCT), a key step towards clinical approval begins: the efficacy and safety of vagus nerve stimulation (VNS) will be systematically investigated across multiple European centers.

What is the baroloop MCT?

The study is a multicenter, prospective clinical trial. It examines the use of baroloop in patients for whom the recommended pharmacological treatment strategy for hypertension has failed. The approval study is being conducted in several specialized clinics across Europe.

Study Objective

The aim of the clinical trial is to demonstrate the clinical efficacy and safety of the baroloop system. The results are intended to support a European approval of the baroloop system for the treatment of patients in whom the recommended pharmacological therapy for hypertension has failed.

Background: Why baroloop?

baroloop selectively stimulates the vagus nerve to activate the body’s natural baroreflex, enabling controlled reduction of blood pressure. The system uses an implantable electrode to provide a long-term therapy option for resistant hypertension—a potentially life-threatening condition.

Press contact
neuroloop GmbH
Breisacher Straße 86, 79110 Freiburg, Germany
E-mail: info@neuroloop.de